Grant: CIHR Fellowship
McGill University
$135,000.00
Generation of a dendritic cell-based vaccine by modulating the expression of protein tyrosine phosphatases.
FY 2011-12
Summary
Dendritic cells (DCs) are essential immune cells in the initiation and maintenance of anti-tumor immunity. DCs capture tumor-derived proteins (antigens) and process them into tumor-peptides that eventually will be presented on their cell surface (process known as antigen presentation) to other immune cells such as T cells. During this process, DCs differentiate from immature to mature DCs, which is characterized by an increased expression of cell surface proteins and production of stimulatory factors (pro-inflammatory cytokines). These events are required for the activation of T cell and the induction of T cell cytotoxic activity (capacity to kill tumor cells by a cell-cell contact dependent mechanism). The maturation status of DCs is therefore crucial to induce an effective anti-tumor response. Nevertheless, DC-based vaccination protocols have
elicited poor clinical responses with no durable tumor rejection and/or prolonged survival.Defects in the DCs number and functions are one of the main factors responsible for the tumour escape from the immune system attack, and these defects contribute in various ways to defects in the T cell cytotoxic activity observed in cancer. The processes of DC maturation, antigen presention and migration to the lymphoid organs (where antigen presentation takes place) are regulated by a variety of enzymes. In particular, a family of protein tyrosine phosphatases (PTPs) can dramatically alter DCs functions (enhance or reduce) and therefore affect T cell activation and anti-tumor responses. We propose to genetically modify DCs by depleting or over-expressing specific PTPs in order to generate fully mature DCs with potent antigen presentation
capacity. Consequently, modified DCs will be resistant to tumor-derived suppression and potent inducers of T cell activation and anti-tumor responses in vivo.
Department
Program
CIHR Fellowship
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
241934
Name
Penafuerte-Diaz Claudia A
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Generation of a dendritic cell-based vaccine by modulating the expression of protein tyrosine phosphatases.
Programtype2
Fellowship Programs
Orgnameinp2
McGill University
Cihramount2
$135,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Antigen Presentation; Co-Stimulatory Molecules; Dendritic Cells; Lymphomas; Maturation; Nk Cell Activation; Pancreatic Cancer; Ptp Protein Kinase Phosphatases; T Cell Activation; Vaccine
Abstract
Dendritic cells (DCs) are essential immune cells in the initiation and maintenance of anti-tumor immunity. DCs capture tumor-derived proteins (antigens) and process them into tumor-peptides that eventually will be presented on their cell surface (process known as antigen presentation) to other immune cells such as T cells. During this process, DCs differentiate from immature to mature DCs, which is characterized by an increased expression of cell surface proteins and production of stimulatory factors (pro-inflammatory cytokines). These events are required for the activation of T cell and the induction of T cell cytotoxic activity (capacity to kill tumor cells by a cell-cell contact dependent mechanism). The maturation status of DCs is therefore crucial to induce an effective anti-tumor response. Nevertheless, DC-based vaccination protocols have
elicited poor clinical responses with no durable tumor rejection and/or prolonged survival.Defects in the DCs number and functions are one of the main factors responsible for the tumour escape from the immune system attack, and these defects contribute in various ways to defects in the T cell cytotoxic activity observed in cancer. The processes of DC maturation, antigen presention and migration to the lymphoid organs (where antigen presentation takes place) are regulated by a variety of enzymes. In particular, a family of protein tyrosine phosphatases (PTPs) can dramatically alter DCs functions (enhance or reduce) and therefore affect T cell activation and anti-tumor responses. We propose to genetically modify DCs by depleting or over-expressing specific PTPs in order to generate fully mature DCs with potent antigen presentation
capacity. Consequently, modified DCs will be resistant to tumor-derived suppression and potent inducers of T cell activation and anti-tumor responses in vivo.
Competitiondate
201110
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Penafuerte-Diaz, Claudia A
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $135,000~ $0~